US Patent

US11020393 — Methods of treating disease with levoketoconazole

Method of Use · Assigned to Strongbridge Dublin Ltd · Expires 2040-03-02 · 14y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of administering levoketoconazole, or a salt thereof, to a subject also being administered a MATE1 substrate or an OCT2 substrate.

USPTO Abstract

Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.

Drugs covered by this patent

Recorlev (LEVOKETOCONAZOLE) · Strongbridge

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3282`	—	Recorlev

Patent Metadata

Patent number: US11020393
Jurisdiction: US
Classification: Method of Use
Expires: 2040-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Strongbridge Dublin Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.